(redirected from Besivance)


(be-si-flox-a-sin) ,


(trade name)


Therapeutic: anti infectives
Pharmacologic: fluoroquinolones
Pregnancy Category: C


Treatment of bacterial conjunctivitis.


Inhibits bacterial DNA synthesis by inhibiting DNA gyrase.

Therapeutic effects

Death of susceptible bacteria with decreased symptoms and sequelae of bacterial conjunctivitis.
Active against CDC coryneform group G, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus lugdunensis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae and Streptococcus salivarius.


Absorption: Minimal absorption follows ophthalmic use.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 7 hr.

Time/action profile

Ophthunknownunknown6–12 hr


Contraindicated in: Contact lens use.
Use Cautiously in: Obstetric: Use during pregnancy only if potential benefit justifies potential risk to fetus; Lactation: Use cautiously during lactation; Pediatric: Safe use in children <1 yr not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • conjunctival redness (most frequent)
  • blurred vision
  • eye irritation
  • eye pain,
  • eye pruritus.


Drug-Drug interaction

None noted.


Ophthalmic (Adults and Children ≥1 yr) One drop in affected eye(s) three times daily (4–12 h apart) for 7 days.


Ophthalmic suspension: 0.6% 5 mL in 7.5 mL bottle

Nursing implications

Nursing assessment

  • Assess eye for signs of infection (swelling, redness, pain, discharge) prior to and periodically during therapy.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Ophthalmic: Invert closed bottle and shake once before use. Remove cap with bottle still inverted. Tilt head back and, with bottle inverted, gently squeeze bottle to instill 1 drop in affected eye 3 times daily (4–12 hrs apart) for 7 days.

Patient/Family Teaching

  • Instruct patient to use besifloxacin as directed, even if feeling better. Do not skip doses or stop therapy early; may lead to decreased effectiveness and resistant infections. Avoid touching applicator to eye, finger, or other areas; may contaminate. Wash hands prior to instillation.
  • Caution patient to avoid wearing contact lenses during therapy.
  • Advise patient to discontinue immediately and notify health care professional if signs or rash or allergic reaction (hives, difficulty breathing, swelling of throat) occur.

Evaluation/Desired Outcomes

  • Resolution of signs and symptoms of infection.
References in periodicals archive ?
08%, Onexton and Acanya Gel--and ophthalmology products including Besivance, Lotemax and Alrex.
08%, Onexton and Acanya Gel and ophthalmology products including Besivance, Lotemax, Alrex, Prolensa , Bepreve and Zylet.
It has two commercial products based on its innovative DuraSite platform approved for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the US by Akorn and Besivance (besifloxacin ophthalmic suspension) 0.
Bausch + Lomb has a broad portfolio of eye health products, including such well-known prescription and O-T-C brands as Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, rent] and Boston; and surgical brands enVista, Storz, Stellaris and Victus.
Bausch + Lomb is a eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and VICTUS.
Besivance, a breakthrough pharmaceutical therapy that can eradicate bacterial conjunctivitis at its source both safely and effectively
Besifloxacin ophthalmic suspension will be marketed as Besivance 0.
The portfolio of the acquired business includes prescription and over-the-counter (OTC) brands like Besivance, Lotemax, Ocuvite and PreserVision as well as some vision care and surgical brands.
M2 PHARMA-April 3, 2013-InSite Vision Incorporated reports sale of Besivance royalty for up to USD16m(C)2013 M2 COMMUNICATIONS
M2 EQUITYBITES-February 5, 2014-InSite Vision receives USD1m in royalties from the sale of Besivance
The company added that ISTAa[euro](tm)s four prescription products, Bromday, Bepreve, Istalol, and Vitrase, will complement its existing prescription ophthalmology products, including Lotemax and Besivance, and branded over the counter (OTC) eye vitamins PreserVision and Ocuvite.